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INTRODUCTION
Multiple sclerosis (MS) is a chronic, inflammatory 
demyelinating disease of the central nervous system 
with complex etiopathogenesis. It has been suggested 
that altered oxidative stress pathway including changed 
regulation of detoxifying enzymes like superoxide 
dismutase, catalase, glutathione peroxidase, paraoxo-
nase and glutathione S-transferases (GSTs) which rep-
resent a defense system against oxidative reactions 
(Ortiz et al. 2013) may greatly contribute to the patho-
genesis of multiple sclerosis (Korpela et al. 1989, 
Powell et al. 1992, Calabrese et al. 1994, Migliore and 
Coppede 2002, Dhib-Jalbut et al. 2006). 
Glutathione (GSH) metabolism is involved in antioxi-
dative protection by affecting individually different 
responses, susceptibility and coping with oxidative stress, 
which is particularly important for mammalian brain tis-
sue. It has been documented that alterations of GSH 
metabolism lead to different levels of nerve cell loss and 
Progression of multiple sclerosis is associated  
with gender differences in glutathione S-transferase P1 
detoxification pathway 
Koraljka Bačić Baronica1, Kristina Mlinac2, Roberta Petlevski3, David Ozretić4, Anton Vladić1,  
Svjetlana Kalanj bognar2&*, and Irena Žuntar5& 
&Authors contributed equally to this work
1Department of Neurology, Clinical Hospital “Sveti Duh”, Zagreb, Croatia; 2 Department for Chemistry and Biochemistry 
and Croatian Inst. for Brain Research, School of Medicine, University of Zagreb, Zagreb, Croatia, *Email: svjetla@mef.hr; 
3Department for Medical Biochemistry and Hematology, Faculty of Pharmacy and Biochemistry, University of Zagreb, 
Zagreb, Croatia; 4Department of Diagnostic and Interventional Radiology, University Hospital Centre Zagreb, Zagreb, 
Croatia; 5Department of Analytical Toxicology, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, 
Croatia
The impact of glutathione S-transferases (GSTs) detoxification pathway on complex pathogenesis and heterogeneity of 
clinical findings in multiple sclerosis (MS), particularly the exact correlation between indicators of clinical severity and 
different GST genotypes, has not yet been fully elucidated. The aim of the study was to assess the relationship between 
disability level in multiple sclerosis (estimated by Kurtzke Expanded Disability Status Scale), disease progression (estimated 
by Multiple Sclerosis Severity Score), the level of brain atrophy and lesion load (determined by MRI) and detoxification 
status (analyzing glutathione S-transferase P1, GSTP1, genotype profile), in a group of 58 MS patients and 68 age/gender-
matched controls. The results present the first evidence on significantly higher frequency of GSTP1 C341T polymorphism 
(C-T transition) in healthy subjects compared to MS patients, suggesting it may act as a moderating factor in developing MS 
clinical phenotype. Gender-dependent distribution of the C341T polymorphism was found in both MS patients and controls, 
with higher frequency of C-T transition in females. In addition, preliminary data showed higher proportion of male MS 
patients with higher median MSSS scores, as well as lower brain atrophy level and lesion load in MS patients carrying the 
C341T mutation. Observed gender difference in distribution of the C341T polymorphism in MS patients, as well as in 
disease progression, suggests that GSTP1 detoxification pathway occurs in a gender-dependent manner and could therefore 
add to clinical severity in male MS patients. 
Key words: multiple sclerosis, clinical severity, glutathione S-transferase P1 detoxification pathway, gender differences
Correspondence should be addressed to S. Kalanj Bognar  
Email svjetla@mef.hr
Received 17 January 2014, accepted 16 May 2014
258  K. Bačić Baronica et al.
neurodegeneration (Ballatori et al. 2009, Al et al. 2013). 
GSTs are supergene family of enzymes which participate 
in GSH metabolism; beside their role in protecting the 
cells from damage caused by oxidized metabolites, GSTs 
are involved in cellular processes such as biotransforma-
tion, detoxification, steroidogenesis, and cell signaling 
(Armstrong 1997, Henderson et al. 1998, Watson et al. 
1998). The pi class of GSTs is most ubiquitous and preva-
lent GST isoenzyme in nonhepatic tissues (Watson et al. 
1998, Migliore and Coppede 2002), appearing also as an 
oligodendrocytic marker (Tamura et al. 2007). The role of 
GSTs gene polymorphisms in the pathogenesis of multi-
ple sclerosis has been supported by several studies mostly 
focused on the analysis of GSTM or GSTT allelic variants 
(Mann et al. 2000, Weatherby et al. 2000, Kantarci et al. 
2002, Stavropoulou et al. 2007, Živković et al. 2013). 
In this study, we investigated the influence of gluta-
thione S-transferase P1 (GSTP1) detoxification path-
way on the clinical phenotype in patients with multiple 
sclerosis. For that purpose, we analyzed the relation-
ship between two estimated GSTP1 genotypes (A313G 
and C341T) and disability level, disease progression, 
level of brain atrophy and lesion load in MS patients in 
comparison with age- and gender-matched healthy 
controls.
METHODS
Subjects
The study group consisted of 126 subjects. The case 
group consisted of 58 patients with diagnosis of the 
relapsing-remitting multiple sclerosis (RRMS; 41 
females, age range: 22–57 years, mean age: 43.1; 17 
males, age range: 18–68 years, mean age: 37.5) hospital-
ized at the Department of Neurology, Clinical Hospital 
“Sveti Duh”, Zagreb, Croatia. All subjects were treat-
ment naïve except standard corticosteroid treatment for 
relapses. No drugs were administered prior to blood 
samples collection. The control group included 68 age- 
and gender-matched healthy subjects (42 females, age 
range: 20–58 years; mean age: 37; 26 males, age range: 
21–71 years; mean age: 35.6) with negative history of 
neuropsychiatric and neurodegenerative disorders. 
Individuals suffering from renal, cardiac, gastrointesti-
nal, endocrine and liver diseases, as well as those suf-
fering from hypertension and asthma, were excluded 
from the study, as were the subjects on any drug/vita-
min/mineral therapy and alcoholics (consuming >50 g 
of alcohol/day). Patients and healthy volunteers which 
participated in the study were informed in details on the 
purpose and methodology of the study and gave their 
informed consent for the involvement in the project. 
The study was approved by the Research Ethics 
Committee of “Sveti Duh” Clinical Hospital, Zagreb, 
Croatia and Research Ethics Committees of the School 
of Medicine and Faculty of Pharmacy and Biochemistry, 
University of Zagreb. 
Estimation of disability level and disease 
progression in patients with multiple sclerosis
The clinical diagnosis of RRMS was established 
according to revised McDonald’s criteria (McDonald 
et al. 2001, Polman et al. 2005) and supported by neu-
rophysiologic tests, laboratory diagnostics and mag-
netic resonance imaging (MRI). Disability status was 
estimated by Kurtzke Expanded Disability Status 
Scale (EDSS) (Kurtzke 1983). According to this meth-
od, three stages of disability are classified as mild 
(EDSS=0–4.0), moderate (EDSS=4.5–5.5) and severe 
disability (EDSS=6.0–9.5). Disease progression was 
determined using Multiple Sclerosis Severity Score 
(MSSS) which takes into account EDSS scores and 
duration of disease, giving information on disease pro-
gression (Roxburgh et al. 2005). Assigned MS Severity 
Score of 5.0 means disease progressing at the median 
rate, while MSSS>5.0 indicates fast progression and 
MSSS<5.0 slower progression of disease. In addition, 
the correlation between disease severity and genotype 
was analyzed, by comparing median MSSS scores in 
different genotype groups of patients (Roxburgh et al. 
2005, online software – University of Cambridge 
NUMSGG 2013). 
Determination of glutathione S-transferase P1 
gene polymorphisms
For the purposes of genotype analysis, genomic 
DNA was isolated from whole blood samples, collect-
ed by venipuncture during morning hours and prior to 
administration of any medication (Miller et al. 1988). 
Two glutathione S-transferase P1 (GSTP1) polymor-
phisms – A313G (105 Ile/Val, A-G transition in GSTP1 
exon 5) and C341T (114 Ala/Val, C-T transition in 
GSTP1 exon 6) – were analyzed by PCR-RFLP meth-
od, according to previously described procedure 
(Žuntar et al. 2004). 
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The relationship between GSTP1 gene polymor-
phisms and serum glutathione S-transferase activity 
was also analyzed in a group of MS patients and con-
trols. Serum GST activity was determined using spec-
trophotometric method on a Trace spectrophotometer 
(Trace Scientific Ltd, Australia) utilising 1-chloro- 
-2,4-dinitrobenzene (CDNB, Sigma) as a substrate 
(Habdous et al. 2002).
Neuroimaging techniques
Additional qualitative and semiquantitative inter-
pretation of MRI findings of MS patients was per-
formed in order to estimate whether brain pathomor-
phological changes are associated with the analyzed 
GSTP1 polymorphisms. MRI findings were compared 
between MS patients/GSTP1 mutation carriers and MS 
patients/mutation non-carriers, carefully selected and 
matched according to gender, age and disease dura-
tion. Neuroimaging was done by conventional MR 
techniques (T1-, T2-weighted and FLAIR sequences in 
multiple planes, with gadolinium enhancement, using 
1.5 T MR device). Independent neuroradiological 
assessment included grading of disease severity imag-
ing markers – atrophy level, number of hypointense 
lesions on T1-weighted images, number of hyperin-
tense lesions on T2-weighted images, and number of 
gadolinium enhanced lesions. Grading of  disease 
Table 1
Relationship between GSTP1 genotypes and gender in patients with multiple sclerosis and age/gender matched controls
MS (n=58) Controls (n=68)
GSTP1 
genotypes
Female  
(n=41)
n (%)
Male  
(n=17)
n (%)
P-value
Female 
(n=42)
n (%)
Male 
(n=26)
n (%)
P-value
GSTP1 exon 5       
AA 19 (46) 7 (41)  21 (50) 16 (62)  
AG 21 (51) 9 (53)  20 (48)  8 (30)  
GG 1 (3)a,e 1 (6)i,m 0.782 1 (2)  2 (8) 0.283 
AG+GG 22 (54)b,f 10 (59)j,n 0.944 21 (50) 10 (38) 0.498
A/G frequency 72/28 68/32 0.643 74/26 77/23 0.742
HWE 0.467 0.723 0.464 0.745
GSTP1 exon 6       
CC 30 (73) 16 (94)  23 (55) 11 (42)  
CT 10 (24) 1 (6)  18 (43) 12 (46)  
TT 1 (3)c,g 0 (0)k,o 0.197 1 (2) 3 (12) 0.243
CT+TT 11 (27)d,h 1 (6)l,p 0.151 19 (45) 15 (58) 0.454
C/T frequency 85/15 97/3 0.007 76/24 65/35 0.121
HWE 1.000 1.000 0.790 1.000
The analyzed genotypes were in Hardy-Weinberg equilibrium (HWE) for the MS patients (n=58) and control group 
(n=68)(P>0.05). (MS), Multiple sclerosis; (P) χ2 test; a P=0.945, female MS vs. female controls; b P=0.909, female MS vs. 
female controls; c P=0.202, female MS vs. female controls; d P=0.129, female MS vs. female controls; e P=0.200, female 
MS vs. male controls; f P=0.336, female MS vs. male controls; g P=0.031, female MS vs. male controls; h P=0.023, female 
MS vs. male controls; i P=0.346, male MS vs. male controls; j P=0.336, male MS vs. male controls; k P=0.003, male MS 
vs. male controls; l P=0.002, male MS vs. male controls; m P=0.703, male MS vs. female controls; n P=0.744, male MS vs. 
female controls; o P=0.015, male MS vs. female controls; p P=0.010, male MS vs. female controls.
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severity imaging markers was done as follows: atrophy 
level was attributed with grade 0 – absent, 1 – mild, 2 
– moderate, 3 – severe; T1- and T2-weighted lesions as 
well as gadolinium enhanced lesions were graded with 
0 – absent, 1 – 1 to 9 lesions, 2 – 10 to 20 lesions, 3 – 
more than 20 lesions.
Statistical analysis
The frequency of each genotype and association 
between cases and controls were estimated by χ2-test 
using the SigmaStat program (version 3.5, Jandel 
Corporation, Chicago, Illinois, USA). Odds ratios (OR) 
and 95% confidence interval (CI) were calculated by 
the MedCalc (version 7.0.0.2., MedCalc Software, 
B-9030 Mariakerke, Belgium) and were used to 
describe the strength of association. Analysis of MSSS 
scores in different genotype groups of MS patients was 
performed by Kruskal-Wallis test (Roxburgh et al. 
2005; online software University of Cambridge 
NUMSGG). Comparison of disease severity neuroim-
aging markers in MS patients-mutation carriers vs. 
non-carriers was done by non-parametric Wilcoxon 
test. Statistical significance was set at 5% for all per-
formed statistical analyses. 
RESULTS
In this study the influence of GSTP1 detoxification 
pathway on clinical phenotype was analyzed in 58 MS 
patients. For this purpose, the relationship between 
estimated GSTP1 genotypes (A313G and C341T) and 
disability level, disease progression, serum glutathione 
S-transferase activity and neuroimaging markers of 
disease severity in MS patients was studied. Significant 
differences in analyzed genotype frequencies and dis-
tribution between MS patients and controls were found 
only in the case of C341T polymorphism. This poly-
morphism was detected in 12 MS patients (11 heterozy-
gotes and 1 homozygote) and in 34 controls (30 
heterozygotes and 4 homozygotes). Surprisingly, sig-
nificantly higher frequency of combined CT+TT geno-
type and of the mutated allele (C-T transition) was 
found in control population as compared to MS group 
(50% vs. 21%; 28% vs. 11%; P=0.003 for genotypes; 
P=0.004 for alleles). The frequency of the A–G transi-
tion, another  GSTP1 polymorphism analyzed in this 
study, was determined at 29% in MS patients and 25% 
in control subjects; no statistically significant differ-
ence was found in the distribution of the GSTP1 
A313G genotypes (P=0.800) and alleles (P=0.633) 
between MS patients and controls. 
Gender distribution of A313G and C341T polymor-
phism was additionally analyzed in both MS patients 
and control group (Table I). C341T polymorphism (C–T 
transition) was found to be significantly more frequent 
in healthy men in comparison with male MS patients 
while no such difference in frequency of C341T muta-
tion was observed in female MS patients vs. healthy 
women (Table I). The study showed statistically sig-
nificant difference between MS females and MS males 
in the distribution of GSTP1 C341T  alleles and sig-
nificantly higher frequency of T allele in female than in 
male MS patients (15% vs. 3%; P=0.007) (Table I). 
Fig. 1. Correlation between GSTP1 genotypes and (a) disability status as measured by EDSS, and (b) disease severity status 
as measured by MSSS, in a group of patients with multiple sclerosis. (EDSS) Expanded Disability Status Scale; (MSSS) 
Multiple Sclerosis Severity Score; *a P=0.033, Kruskal-Wallis test
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In this study, total serum GST activity of MS 
patients and controls (103.96±16.88 U/L vs. 102.91±26.03 
U/L, P=0.823, t-test) was analyzed and the relationship 
between GSTP1 gene polymorphisms and enzyme 
activity in a group of MS patients was additionally 
estimated. Comparison of total serum GST activities 
in MS patients carrying AA vs. combined AG+GG 
genotype (108.42±20.55 U/L vs. 106.29±14.86 U/L), as 
well as CC vs. CT+TT genotype (107.99±18.91 U/L vs. 
104.47±11.09 U/L) did not reveal statistical difference, 
and no connection was found between enzyme activity 
and analyzed GSTP1 genotypes. 
In order to determine the possible effects of different 
GSTP1 genotypes on the clinical phenotype of multiple 
sclerosis, the disability level and disease progression 
were estimated by EDSS scores and MSSS testing in 
all MS patients. It was observed that majority of male 
and female MS patients/mutation carriers presented 
with mild disability (7 of 10 male, and 15 of 22 female 
MS patients/mutation carriers had EDSS score =0–4.0). 
There was no correlation between GSTP1 A313G and 
C341T genotypes and disability level of MS patients, 
estimated by EDSS scores (P=0.504; P=0.588) (Fig. 1). 
Additional determination of disease progression by 
MSSS testing showed high proportion of MS patients/
mutations carriers with MSSS>5.000, indicating so-
called fast disease progressors, in both male and female 
MS patients (8 of 10 male, and 11 of 22 female MS 
patients/mutation carriers). Also, higher median MSSS 
score was determined in male (median =6.1, range 
=4.568–9.496) vs. female (median =5.382, range 
=1.889–9.453) MS patients/mutation carriers. MSSS 
Fig. 2. Axial T1- weighted (A, B) and T2- weighted (C, D) MR images in two multiple sclerosis female patients, confirmed 
as C341T mutation carrier (A and C) and C341T mutation non-carrier (B and D) matched for age, gender and disease dura-
tion. T1 and T2 lesions are indicated by white arrows. 
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testing showed that patients carrying GG genotype 
(A313G polymorphism) have statistically significantly 
higher median MSSS score than patients with AA or 
AG genotype (P=0.032, Kruskal-Wallis test) while no 
such correlation was found for TT genotype (C341T 
polymorphism) (Fig. 1). 
Qualitative and semiquantitative analysis of MRI 
findings showed significantly lower atrophy grade and 
smaller number of T2-weighted lesions in MS patients-
carriers of C341T mutation when compared with muta-
tion non-carriers matched for gender, age and disease 
duration (Wilcoxon test, P<0.05)(Fig. 2). A notable dif-
ference was also a smaller number of hypointense 
lesions on T1- weighted images in MS patients-carriers 
of C341T mutation.  Figure 2 shows representative MR 
images, revealing described difference in lesion load in 
two female MS patients: C341T mutation carrier (age: 
42, duration of disease: 6 years, MSSS 6.807, EDSS 
4.0) vs. C341T mutation non-carrier (age: 47 years, 
duration of disease: 9 years, MSSS 3.448, EDSS 2.5). 
DISCUSSION
Recent studies on glutathione metabolism showed 
that any alteration in this important antioxidative pro-
tective system affects the level of neurodegeneration 
and nerve cell loss (Al et al. 2013), and that decreased 
GSH content may be correlated with a clinical severity 
of multiple sclerosis in humans (Ljubisavljevic et al. 
2014). In addition, there is evidence on significant 
reduction of GSH in grey matter and white matter 
lesions in multiple sclerosis patients, as revealed by 
MR spectroscopic imaging of glutathione (Srinivasan 
et al. 2010). Investigation of genes coding for GSTs, 
enzymes involved in the antioxidative GSH utilization, 
as well as on the role of GSTs gene polymorphisms in 
the pathogenesis of multiple sclerosis led to a conclu-
sion that genetically determined vulnerability for oxi-
dized metabolites may contribute to alteration of 
detoxification pathway via GSTs in multiple sclerosis 
(Mann et al. 2000, Weatherby et al. 2000, Kantarci et 
al. 2002, Stavropoulou et al. 2007, Živković et al. 
2013). Majority of these studies focused on analysis of 
GSTM and GSTT allelic variants.
In our study, two polymorphisms in the GSTP1 gene 
were estimated – A313G and C341T. The A313G poly-
morphism was described previously in MS patients 
(Mann et al. 2000). Our results on the distribution of 
the A313G genotypes and alleles in MS patients are 
similar to those obtained by Mann and coworkers 
(2000)  in the study which analyzed GSTP1 (A313G), 
GSTM1, GSTM3 and GSTT1 genotypes in a large 
group of MS patients. In Mann s´ study, only combined 
GSTM1 null/GSTP1 AA genotype, as well as GSTT1 
and GSTM1 null genotypes, correlated negatively to 
long-term prognosis of disease (Mann et al. 2000). 
Data on the C341T polymorphism analyzed in our 
study have not yet been reported in available literature. 
We observed significantly higher frequency of C–T 
transition and combined CT+TT genotype in control 
population vs. MS patients, as well as significantly 
higher frequency of that mutation in healthy male 
population in comparison with male MS patients. This 
finding is in line with the hypothesis that carriers of 
the C341T polymorphism might be less susceptible to 
developing MS clinical phenotype. In addition, 
observed gender-dependent distribution of C–T transi-
tion in both healthy women and MS female patients 
when compared to male controls and patients, indi-
cates gender differences in GSTs oxidative detoxifica-
tion actions. Stravropoulou and colleagues (2007) 
suggested a role of GSTs in a gender-dependent man-
ner in the MS pathogenesis providing possible expla-
nation for higher disease prevalence amongst females 
due to observed higher incidence of GSTM1 null geno-
types in female MS patients. Gender-dependent distri-
bution of GSTP1 C341T genotype in MS patients, 
found in our study, as well as hypothesized moderating 
role of C341T polymorphism may also contribute to 
generally less severe disease course and better progno-
sis observed in female than in male MS patients.
Interestingly, interpretation of neuroimaging mark-
ers of disease severity confirmed that MS patients 
carrying C341T mutation had lower atrophy grade and 
lesion load in comparison with MS patients/mutation 
non-carriers, even regardless of their EDSS and MSSS 
scores. A notable difference was also smaller number 
of hypointense lesions on T1-weighted images, seen as 
areas of low signal intensity compared to normal-ap-
pearing white matter. These so-called ‘black holes’ 
have various pathological substrates depending on the 
disease stage; it has been suggested that the number of 
chronic ‘black holes’ which are more frequent in 
patients with progressive disease could serve as sur-
rogate markers of disability in MS (Truyen et al. 1996, 
Rovira and Leon 2008). Our observation on lower 
atrophy grade and lesion load in MS patients carrying 
C341T mutation  is based on a small sample size, how-
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ever it supports the idea on putative moderating role of 
this mutation in multiple sclerosis pathogenesis. 
The effect of detected GSTP1 polymorphisms on 
the enzyme activity was assessed by determination of 
total GST activity in serum samples of MS patients 
and controls. It has been previously evidenced that 
A313G and C341T polymorphisms affect enzyme 
activity in vitro (Ali-Osman et al. 1997, Habdous et al. 
2004). Also, a recent study, dealing with various 
peripheral markers of oxidative stress in relapsing-re-
mitting multiple sclerosis, showed significantly lower 
total GST activity in erythrocytes derived from MS 
patients when compared with controls (Tasset et al. 
2012). The results from that study are not fully compa-
rable with our results, as we used a different method 
for measuring the enzyme activity in serum samples, 
not erythrocytes. We did not find a direct connection 
between serum GST activity and the GSTP1 geno-
types when comparing MS patients/carriers and MS 
patients/non-carriers of either A313G or C341T muta-
tion. This is not surprising, as many GST genes regu-
late the production of the enzyme and a single abnor-
mality may not be adequate to reduce the total level of 
GST activity (Sheehan et al. 2001). Also, measured 
total serum GST activity is a sum of pi and alpha GST 
isoenzymes activity (Habdous et al. 2002, 2004), and 
thus may be related to different GSTP1 and GSTM 
polymorphisms. Difficulty in interpretation of our 
result might be related to recently reported limitations 
of the method used for GST activity determination as 
well (Fabrini et al. 2012). Final conclusion referring to 
exact relationship of GST enzyme activity and differ-
ent GST genotypes in MS should be furthermore sup-
ported and clarified by studies using a larger sample 
size. In addition, keeping in mind a high expression of 
pi class of GSTs in brain tissue, it would be tempting 
to explore the effects of GSTP1 polymorphisms on 
brain GST activity and probable consequent alterations 
of brain GSH metabolism in multiple sclerosis. 
In order to investigate the influence of analyzed 
GSTP1 gene polymorphisms on the clinical pheno-
type, we estimated disability level and disease pro-
gression in MS patients by EDSS scores and MSSS 
testing. EDSS is a standard clinical tool for estimation 
a disability level in multiple sclerosis but is limited to 
single assessment within the course of the disease, giv-
ing no insight into disease progression. This explains 
significant variations of individual EDSS results 
depending whether the estimation was performed dur-
ing disease relapse or remission. We did not manage to 
find a correlation between GSTP1 A313G and C341T 
genotypes and disability level of MS patients, as esti-
mated by EDSS scores. It is important to note that 
none of the MS patients was a carrier of independent 
C341T mutation (unlike control subjects), meaning that 
at least a part of analyzed MS phenotypic characteris-
tics are a consequence of combined A–G and C–T 
genotypes. However, additional determination of dis-
ease progression by MSSS testing showed that patients 
bearing mutated A313G genotype (GG) are fast dis-
ease progressors; such a correlation was not found for 
C341T genotypes and MSSS. The advantage of the 
MSSS method is that it takes into account a disability 
level score as well as the duration of the disease. MSSS 
is thus an accurate method for correlation analysis of 
groups of patients with different genotypes and dis-
ease progression and for identifying factors influenc-
ing disease progression such as gene polymorphisms. 
Our observation on higher proportion of male MS 
patients/mutation carriers with MSSS scores >5.000 
and higher median MSSS score in male than in female 
MS patients is in line with described gender-dependent 
clinical characteristics of multiple sclerosis – higher 
incidence, milder clinical features and better prognosis 
in majority of female than in male MS patients 
(Tomassini and Pozzilli 2009). Additional evidence on 
gender as one of determining factors for relapse inci-
dence and disease progression is provided by a recent 
cohort study showing higher relapse frequency in 
females than in males while lower female to male sex 
ratio was observed in primary progressive multiple 
sclerosis (Kalincik et al. 2013). Finally, it can be con-
cluded that both gender differences and antioxidative 
glutathione protection system are implicated in com-
plex and multifactorial etiopathogenesis of multiple 
sclerosis.
CONCLUSION
This study presents significantly different distribu-
tion and higher frequency of GSTP1 C341T polymor-
phism in healthy individuals in comparison with MS 
patients, suggesting its possible role as a moderating 
factor in developing MS clinical phenotype. Observed 
gender difference in distribution of C341T polymor-
phisms between female and male MS patients indicates 
that GSTP1 detoxification pathway may occur in a 
gender-dependent manner. Our results showing associa-
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tion of investigated GSTP1 gene polymorphisms with 
indicators of disability, disease progression and neu-
roimaging findings demonstrate a probable influence of 
GSTP1 on clinical course and disease severity, and its 
involvement in pathogenesis of multiple sclerosis.
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